Investigating Arabinogalactan's Therapeutic Potential in Alzheimer's Disease: In-Vivo Evidence

Abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, β-amyloid (Aβ) accumulation, oxidative stress, and neuroinflammation. Natural polysaccharides such as arabinogalactan (AG) have gained attention due to their antioxidant and neuroprotective properties. Objective: To investigate the therapeutic potential of arabinogalactan in an in vivo model of Alzheimer’s disease. Methods: Alzheimer-like pathology was induced in rodents using standard neurotoxic agents. Animals were treated with arabinogalactan of various doses 200 & 400mg/kg p.o., and cognitive performance was evaluated using behavioural models. Results: Arabinogalactan significantly improved cognitive functions, reduced oxidative stress, attenuated neuroinflammation, and decreased amyloid accumulation in treated animals. Conclusion: Arabinogalactan exhibits promising neuroprotective activity and may serve as a potential therapeutic candidate for Alzheimer’s disease.